Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Inhibikase Therapeutics, Inc. (IKT) vs SAB Biotherapeutics, Inc. (SABS)

Inhibikase Therapeutics, Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and SAB Biotherapeutics, Inc. are of similar size ($304.8M and $293.0M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −60.3%. Across the 14 metrics below, SAB Biotherapeutics, Inc. leads on 8 and Inhibikase Therapeutics, Inc. on 6.

Valuation

Metric IKT SABS Biotechnology median
P/E n/m n/m 7.88
P/S 1,380.49 161.23 11.47
P/B 2.35 1.22 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 770.06 100.03 10.73
Earnings yield (20.87%) (19.45%) (28.84%)
Free cash flow yield (11.85%) (21.89%) (23.03%)

Profitability

Metric IKT SABS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (51.96%) (19.21%) (57.72%)
Return on assets (48.04%) (16.24%) (49.22%)
Return on invested capital 0.00% (38.97%) 0.00%

Growth

Metric IKT SABS Biotechnology median
Revenue growth (TTM) 110.93% (60.26%) 5.64%
EPS growth (last fiscal year) 57.76% 78.53% —
Revenue growth, 5-year CAGR (42.21%) — 8.40%
Net income growth, 5-year CAGR 0.00% (26.69%) 0.00%

Health

Metric IKT SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 15.82 9.22 4.73
Net debt to EBITDA 3.44 2.03 0.96

Dividend

Metric IKT SABS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IKT SABS Biotechnology median
Market cap 293.03m 304.80m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack